OncoMatch/Clinical Trials/NCT07152041
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
Is NCT07152041 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies olverembatinib for acute lymphoblastic leukemia (all) philadelphia chromosome-positive (ph+).
Treatment: olverembatinib — This prospective clinical trial evaluates the effectiveness and safety of "chemotherapy-light" regimen incorporating the third-generation TKI olverembatinib, the bi-specific CD3/CD19 T cell engager blinatumomab, and the BCL-2 selective inhibitor venetoclax for newly diagnosed pediatric/adolescent patients with Ph+ ALL. The CCCG-Ph+ B-ALL-2025 protocol will be modified as following compared to the CCCG-ALL-2020 protocol
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: ABL1 fusion
Required: BCR fusion
Prior therapy
Cannot have received: glucocorticoid
Exception: less than 14 days within one month before enrollment
Treated with glucocorticoids for ≥14 days within one month before enrollment
Cannot have received: targeted inhibitor
Exception: less than or equal to 7 days within one month before enrollment
targeted inhibitor for > 7 days within one month before enrollment
Cannot have received: chemotherapy
any chemotherapy or any systemic anticancer therapy (including but not limited to any TKI) or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression)
Cannot have received: systemic anticancer therapy
any chemotherapy or any systemic anticancer therapy (including but not limited to any TKI) or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression)
Cannot have received: tyrosine kinase inhibitor
any chemotherapy or any systemic anticancer therapy (including but not limited to any TKI) or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression)
Cannot have received: radiotherapy
Exception: emergency radiotherapy to relieve airway compression
any chemotherapy or any systemic anticancer therapy (including but not limited to any TKI) or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify